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Cleveland, Ohio
The use of the implantable left ventricular assist device
(LVAD) for patients before a heart transplant is evolving
and becoming more common. Almost all U.S. cardiac
transplant programs have an implantable LVAD, either the
HeartMate (Thoratec, Oakland, California) or Novacor
(World Heart, Ottawa, Canada). With better technology,
more predictable clinical results and greater widespread
acceptance, the role of these devices has changed from
something you “have to do” to save the patient’s life to
the provocative subject of the article in this issue of the
Journal by Aaronson et al. (1) is this something you
“should do” to ensure optimal utilization of scarce donor
hearts?
See page 1247
Aaronson et al. (1) at the University of Michigan com-
piled data from their experience suggesting that patients
bridged-to-transplantation with an LVAD were more likely
to survive to transplantation than those receiving inotropes:
81 5% in the LVAD group vs. 64 11% for the inotrope
group (p  NS). Post-transplant survival was significantly
better for the LVAD group at three years (95  4% vs. 65
 10%; p  0.007). Therefore, overall survival was better
for the LVAD group (77  6% vs. 44  9%: p  0.01). In
summary, patients at their institution who received an
LVAD were more likely to be alive three years after the
decision was made to bridge them to transplantation, than
were patients who continued receiving inotropes before
transplantation.
Analysis of the article is difficult because of the critical
issues at the point of decision making, the time at which
LVADs are chosen in favor of inotropic support. All of the
patients who eventually ended up on LVADs were receiving
inotropes, and many were receiving multiple inotropes,
other assist devices or an intra-aortic balloon pump. If the
conditions of the inotrope-dependent patients became
worse, then most patients ended up in the LVAD group.
The implication of this article is that perhaps patients were
better off if their conditions became worse and they even-
tually required an LVAD. It is sometimes hard to convince
the patient and his or her family (let alone the insurance
company) that another operation would be better for them
in the long run. However, there are many reasons to think
that this may be true.
The implantable LVADs have improved so that the most
commonly used devices are electric, portable, allow for
hospital discharge before transplant and generally provide
an acceptable quality of life (2–4). Patients can be rehabil-
itated from their end-stage cardiac condition with associ-
ated cardiac cachexia and undergo physical as well as
physiologic rehabilitation (3–5). It is not uncommon to
perform a transplant in an LVAD recipient who is exercis-
ing regularly, has rebuilt muscle mass and has normal
laboratory values. While the patient’s condition is stable on
LVAD support, the transplant team can wait for an ideal
donor to be offered. The sense of urgency to perform a
transplant in the patient before some major adverse event
occurs has been diminished. While the earliest experience
with the devices were sometimes troubled by mechanical or
electrical failures or thromboemboli, recent experience with
both the HeartMate and Novacor devices shows significant
improvements with these complications due to device de-
sign changes and improvements (6). Continuing instead
with prolonged inotropes before transplantation may lead to
a very lengthy hospitalization for some patients, especially
those with elevated preformed antibodies or large blood type
O patients. Furthermore, the potential for rehabilitation can
be very limited because of the patient’s overall physical
activity level. The patient may become less active and,
therefore, at risk for other complications such as deep vein
thrombosis, pulmonary emboli, multiple organ dysfunction
and sudden cardiac death. Because of this potential scenario,
there is an urgency to perform transplantation in these
patients. Therefore, the transplant team may choose “mar-
ginal” donors, older donors or donors without clearly de-
fined coronary anatomy (example: a 50-year-old male donor
with a smoking history or hypertension) (7). The demo-
graphics, height and weight of the donors in this report may
not reflect the entire picture of the donor which includes
factors such as the amount of inotropes required, the
ejection fraction by echocardiography, size discrepancy vs.
the recipient, the amount of “down time” and the risk
factors for coronary artery disease. Perhaps the tendency
to wait for ideal donors for patients in stable condition
with LVAD may account for their higher late survival
than inotrope-dependent patients at the University of
Michigan.
However, all is not well with the current situation of
LVADs. The patient has to undergo the psychological and
physical trauma of another operation. For many patients
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with ischemic cardiomyopathy, the LVAD implantation is a
second or even third operation (8). Perioperative bleeding is
a significant complication. Furthermore, the bleeding may
lead to increased preformed antibodies that makes trans-
plantation extremely difficult in some patients (9). Perhaps
the most common morbidity, however, is blood stream
infection. In a recent report, over 60% of patients had blood
stream infections during LVAD support (10). Furthermore,
in the results from the Randomized Evaluation of Mechan-
ical Assistance Therapy as an alternative in Congestive
Heart failure (REMATCH) trial, permanent destination
therapy using LVADs, 41% of the deaths in the LVAD
recipients were related to infection (11). Although the risk
of stroke and device failure have been reduced, they have not
been eliminated. Also, the logistics of arranging outpatient
care requires a well trained medical team who are available
at all times. The coordination of hospital discharge includes
extensive training of the patient, usually with a family
member or close friend, arrangements for outpatient hous-
ing or maintenance of the patient at home, training of
emergency paramedical personnel near the patient so that
the patient can be emergently returned to the medical center
if there is a problem and a team of LVAD coordinators
who manage outpatient education as well as the outpa-
tient clinic (12). Aside from the cost of the device itself
(approximately $70,000 U.S. dollars), the implant sur-
gery, intensive care unit and hospital stay and coordina-
tion of outpatient care may contribute to a very high bill.
This is especially true if the patient is developing multiple
organ failure and requires prolonged ventilatory support
or dialysis. Therefore, for inotrope-dependent patients
who are being carefully monitored in the hospital setting,
who are active and exercise with supervision, who have no
evidence of impending multiple organ failure, and who
have no unusual reason so that their wait for a donor
would be exceptionally long, most clinicians will continue
with inotropes until transplantation and will not proceed
with LVAD insertion unless one of those conditions
changes.
A single-center study, such as this from the University of
Michigan, always has to be interpreted in light of more
general results. In particular, the difference in three-year
survival seen after heart transplantation in their patients was
different than in other single-center studies, or from the
registry of the International Society of Heart and Lung
Transplantation or the Cardiac Transplant Research Data-
base (CTRD) (9,13,14). In particular, in one large study,
the CTRD compared 502 patients bridged-to-transplant
with an LVAD vs. 1,514 who received intravenous ino-
tropes (13). There was no significant difference in the early
or late survival. The 65% three-year survival for the
inotrope group in this report seems low compared to
most contemporary registries in which one would expect
survival of approximately 75% to 85%. When compared
to the very high three-year survival in the LVAD group
(95  4%) this presents a strikingly significant difference
(p  0.007), but perhaps not reflective of broader
experience.
Weighing all of these potential risks and benefits of
LVAD versus prolonged inotropes for individual patients
can be very difficult. Additional factors such as availability of
donors in a particular region, the experience of the LVAD
surgical team and even reimbursement from the insurance
carrier for the LVADs are factors that impact on the
decision. However, the picture is becoming clearer that once
a patient evolves beyond the stage of being a “stable”
inotrope-dependent patient, LVADs are not something
that you “have to” use, but something you “should use.” The
severity of the cardiac illness has provided a form of natural
selection. The patients with the most severe disease are
selected to require LVADs. Interestingly, this may favor
some patients in the long run. Since the risks of the devices
are lower than they have been before, and the opportunity to
obtain an ideal donor will be higher, this will become the
natural selection for patients with deteriorating end-stage
cardiac disease. The implications are that more and more
patients will become outpatients on LVADs waiting for
transplant. Eventually, the day will gradually arrive when
outpatients in stable condition are waiting for durable
LVADs for scarce donor hearts that will not be expected to
arrive. In this scenario, the LVAD may end up being a
permanent implant or destination therapy because the
patient and physician have decided that the LVAD is safer
than the morbidity and mortality of immunosuppression
and transplantation.
Reprint requests and correspondence: Dr. Patrick M. Mc-
Carthy, Department of Thoracic and Cardiovascular Surgery,
9500 Euclid Avenue, F25, Cleveland, Ohio 44195. E-mail:
mccartp@ccf.org.
REFERENCES
1. Aaronson KD, Eppinger MJ, Dyke DB, Wright S, Pagani FD. Left
ventricular assist device therapy improves utilization of donor hearts.
J Am Coll Cardiol 2002;39:1247–54.
2. McCarthy PM, Smedira NG, Vargo RL, et al. One hundred Heart-
Mate LVAD patients: evolving concepts and technology. J Thorac
Cardiovasc Surg 1998;115:904–12.
3. Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation
of the HeartMate vented electric left ventricular assist system in
patients awaiting heart transplantation. J Thorac Cardiovasc Surg
2001;122:1186–95.
4. Dew MA, Kormos RL, Winowich B, et al. Quality of life outcomes in
left ventricular assist in-patients and out-patients. ASAIO J 1999;45:
218–25.
5. McCarthy PM, Savage RM, Fraser CD, et al. Hemodynamic and
physiologic changes during support with an implantable left ventricular
assist device. J Thorac Cardiovasc Surg 1995;109:409–18.
6. Kasirajan V, McCarthy PM, Hoercher KJ, et al. Clinical experience
with long-term use of implantable left ventricular assist devices:
indications, implantation, and outcomes. Semin Thorac Cardiovasc
Surg 2000;12:229–37.
7. Hoercher K, Young JB, Stewart RW, et al. Has the use of “marginal”
donors increased morbidity and mortality? A single center experience
(abstr). J Heart Lung Transplant 1998;17:67.
8. McCarthy PM, Smedira NG. Implantable LVAD insertion in pa-
tients with previous heart surgery. J Heart Lung Transplant 2000;19
Suppl 8:S95–100.
1256 McCarthy JACC Vol. 39, No. 8, 2002
Editorial Comment April 17, 2002:1255–7
9. Massad MG, McCarthy PM, Smedira NG, et al. Does successful
bridging with the implantable left ventricular assist device affect
cardiac transplantation outcome. J Thorac Cardiovasc Surg 1996;112:
1275–83.
10. Gordon SM, Schmitt SK, Jacobs M, et al. Nosocomial bloodstream
infections in patients with implantable left ventricular assist devices.
Ann Thorac Surg 2001;72:725–30.
11. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left
ventricular assist device for end-stage heart failure. N Engl J Med
2001;345:1435–93.
12. Catanese KA, Goldstein DJ, Williams DL, et al. Out-patient left
ventricular assist device support: a destination rather than a bridge.
Ann Thorac Surg 1996;62:646–52.
13. Jaski BE, Kim JC, Naftel DC, et al. Cardiac transplant outcome of
patients supported on left ventricular assist device vs. intravenous
inotropic therapy. J Heart Lung Transplant 2001;20:449–56.
14. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The
registry of the International Society for Heart and Lung Transplan-
tation: eighteenth official report—2001. J Heart Lung Transplant
2001;20:805–15.
1257JACC Vol. 39, No. 8, 2002 McCarthy
April 17, 2002:1255–7 Editorial Comment
